Resistance to Some New Drugs and Prevalence of ESBL- and MBL-Producing Enterobacteriaceae Uropathogens Isolated from Diabetic Patients
- PMID: 36556490
- PMCID: PMC9788504
- DOI: 10.3390/life12122125
Resistance to Some New Drugs and Prevalence of ESBL- and MBL-Producing Enterobacteriaceae Uropathogens Isolated from Diabetic Patients
Abstract
Diabetes is a leading non-communicable disease and a risk factor for relapsing infections. The current study was aimed at investigating the prevalence and antibiotic susceptibility of carbapenem-resistant (CR) uropathogens of the family Enterobacteriaceae in diabetic patients. The data of 910 bacterial isolates was collected from diagnostic laboratories during January 2018 to December 2018. The bacterial isolates were identified using traditional methods including colonial characteristics, biochemical tests, and API (20E). Antimicrobial susceptibility and phenotypic characterization of ESBL, MBLs, and KPC was determined by utilizing CLSI recommended methods. The phenotypically positive isolates were further analyzed for resistance-encoding genes by manual PCR and Check-MDR CT103XL microarray. Susceptibility to colistin and cefiderocol was tested in accordance with CLSI guidelines. The data revealed that most of the patients were suffering from type 2 diabetes for a duration of more than a year and with uncontrolled blood sugar levels. Escherichia coli and Klebsiella pneumoniae were the most frequently encountered pathogens, followed by Enterobacter cloacae and Proteus mirabilis. More than 50% of the isolates showed resistance to 22 antibiotics, with the highest resistance (>80%) against tetracycline, ampicillin, and cefazolin. The uropathogens showed less resistance to non-β-lactam antibiotics, including amikacin, fosfomycin, and nitrofurantoin. In the phenotypic assays, 495 (54.3%) isolates were found to be ESBL producers, while ESBL-TEM and -PER were the most prevalent ESBL types. The resistance to carbapenems was slightly less (250; 27.5%) than ESBL producers, yet more common amongst E. coli isolates. MBL production was a common feature in carbapenem-resistant isolates (71.2%); genotypic characterization also validated this trend. The isolates were found to be sensitive against the new drugs, cefiderocol and eravacycline. with 7−28% resistance, except for P. mirabilis which had 100% resistance against eravacycline. This study concludes that a few types of ESBL and carbapenemases are common in the uropathogens isolated from the diabetic patients, and antibiotic stewardship programs need to be revisited, particularly to cure UTIs in diabetic patients.
Keywords: E. coli; K. pneumoniae; antimicrobial resistance; type 2 diabetes; β-lactamase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoniae.J Med Microbiol. 2022 Oct;71(10). doi: 10.1099/jmm.0.001592. J Med Microbiol. 2022. PMID: 36301611
-
Molecular characteristics and antibiotic resistance profiles of Escherichia coli strains isolated from urinary tract infections in children admitted to children's referral hospital of Qom, Iran.Ann Ig. 2019 May-Jun;31(3):252-262. doi: 10.7416/ai.2019.2288. Ann Ig. 2019. PMID: 31069370
-
A Comparative In Vitro Sensitivity Study of "Ceftriaxone-Sulbactam-EDTA" and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit.Indian J Crit Care Med. 2020 Dec;24(12):1213-1217. doi: 10.5005/jp-journals-10071-23573. Indian J Crit Care Med. 2020. PMID: 33446975 Free PMC article.
-
Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202. doi: 10.1111/j.1469-0691.2007.01852.x. Clin Microbiol Infect. 2008. PMID: 18154548 Review.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
Cited by
-
An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.Life (Basel). 2023 Jun 21;13(7):1427. doi: 10.3390/life13071427. Life (Basel). 2023. PMID: 37511802 Free PMC article. Review.
-
Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates.Mol Biol Rep. 2025 Apr 15;52(1):388. doi: 10.1007/s11033-025-10446-x. Mol Biol Rep. 2025. PMID: 40232532
-
In Vitro Activity of New β-Lactamase Inhibitor Combinations against blaNDM, blaKPC, and ESBL-Producing Enterobacteriales Uropathogens.Antibiotics (Basel). 2023 Sep 25;12(10):1481. doi: 10.3390/antibiotics12101481. Antibiotics (Basel). 2023. PMID: 37887182 Free PMC article.
References
-
- Hicks C.W., Canner J.K., Mathioudakis N., Lippincott C., Sherman R.L., Abularrage C.J. Incidence and Risk Factors Associated With Ulcer Recurrence Among Patients With Diabetic Foot Ulcers Treated in a Multidisciplinary Setting. J. Surg. Res. 2020;246:243–250. doi: 10.1016/j.jss.2019.09.025. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous